Prostate Cancer
4,375
639
960
2,140
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
757 trials with published results (17%)
Research Maturity
2140 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.3%
409 terminated out of 4375 trials
84.0%
-2.6% vs benchmark
10%
443 trials in Phase 3/4
35%
757 of 2140 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2140 completed trials
Clinical Trials (4375)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)